Loading stock dataβ¦
$1.50-0.04 (-2.60%)
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Evotec SE in the Healthcare sector is trading at $1.50 with a market capitalization of $579M. Wall Street consensus targets $4.23 (3 analysts), implying a +181.8% move over the next 12 months. The stock is currently near its 52-week low of $1.33, remaining 41.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $143.48Mβ | $156.64Mβ | $253.27Mβ | $163.89Mβ | $171.24M |
| Gross Profit | -$1.58Mβ | -$1.57Mβ | $78.46Mβ | -$62,000β | $8.59M |
| Operating Income | -$89.32Mβ | -$46.42Mβ | $37.21Mβ | -$44.61Mβ | -$28.60M |
| Net Income | -$46.65Mβ | -$121.94Mβ | $14.62Mβ | -$43.09Mβ | -$43.48M |
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Β Evotec Biologics. The company is developing...